Trofinetide
≈ 1 min read
Names in other languages
No names in other languages are held for this entry yet.
Article bodies are English and are not machine-translated. A name in another language is not a translation of the article.
Trofinetide, sold under the brand name Daybue among others, is a medication used for the treatment of Rett syndrome. It is taken by mouth. The most common adverse reactions include diarrhea and vomiting. Trofinetide was approved for medical use in the United States in March 2023. The US Food and Drug Administration considers it to be a first-in-class medication.
Trofinetide, sold under the brand name Daybue among others, is a medication used for the treatment of Rett syndrome. It is taken by mouth. The most common adverse reactions include diarrhea and vomiting. Trofinetide was approved for medical use in the United States in March 2023. The US Food and Drug Administration considers it to be a first-in-class medication. The US Food and Drug Administration (FDA) evaluated the efficacy and safety of trofinetide based on a randomized, double-blind, placebo-controlled, 12-week study (Study 1; NCT04181723) of participants with Rett syndrome 5 to 20 years of age. Participants were randomized to receive trofinetide (N=93) or matching placebo (N=94) for 12 weeks. The dose of trofinetide was based on participant weight to achieve similar exposure in all participants. The FDA granted the application for trofinetide priority review, orphan drug, and fast track designations.
Text derived from https://en.wikipedia.org/w/index.php?oldid=1373826505 under CC BY-SA 4.0; modifications have been made.